Board approves allotment of shares to promoter Shankar Varadharajan following warrant conversion under SEBI Regulation 30 disclosure
Paid-up equity capital rises to Rs 973.19 crore following allotment to eligible employees
Board approves five-year appointment, subject to shareholder nod through postal ballot
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
Capital infusion to accelerate Earendil’s R&D platform
The endorsement follows overwhelming support for the share swap preceding the merger,
Subscribe To Our Newsletter & Stay Updated
